Replimune Group, Inc.
$80 Million - Follow-OnJoint Bookrunner
Reata Pharmaceuticals, Inc.
$439 Million - Follow-OnJoint Bookrunner
$98 Million - Initial Public OfferingJoint Bookrunner
Life Science Tools and Diagnostics / Liquid Biopsy Insights Series: Assessing Test Performance and Technologies
REGN / Is REGN Becoming the TIVO of Biopharma? / Outperform
Medical Supplies and Devices / Survey Highlights Market Share Gain Potential is Real for Spine Robotics Players